Elizabeth Cairns

Duality Biologics and BioNTech say interim data on one of their partnered ADCs look encouraging, with a preliminary cut from the trial showing that nearly …

Olema presented Phase 1b/2 trial data for palazestrant combined with Novartis's Kisqali in ER-positive, HER2-negative breast cancer patients. Among 62 patients, six-month progression-free survival was 73% overall, with 81% in ESR1-mutant patients and 70% in wild-type patients. The company plans the pivotal OPERA-2 trial in the first-line setting.

Pfizer and its partner Arvinas may have landed on a CDK4/6 inhibitor to use in combination with their oral estrogen receptor degrader in breast cancer …

After a mid-stage failure in atopic dermatitis, Q32 Bio plans to take bempikibart forward in alopecia instead, despite a trial in that indication also coming …

Data from a Phase 3 study in second-line breast cancer showed that Eli Lilly's oral SERD reduced the risk of progression or death among patients …

iTeos Therapeutics will set aside inupadenant following lackluster mid-stage data in non-small cell lung cancer. The company will focus on its TIGIT therapies instead, with …

Biohaven reports BHV-1300's lowest dose reduced IgG by 60%+ in trial, below analysts' 70-80% target. Drug shows promise for rheumatoid arthritis treatment.

Novo Nordisk said its highly anticipated Phase 3 readout showed that CagriSema only managed 22.7% weight loss, failing to hit the 25% benchmark the company …

Novo Nordisk finally won US approval for its hemophilia drug Alhemo following the product's rejection by the FDA last year. The once …

The weaker-than-hoped weight loss seen with Novo Nordisk's CagriSema knocked the company's shares badly on Friday. The Danish group spearheaded the GLP …